New York, NY – 04 January 2018 – Glycotest Inc., announced today that it successfully completed a clinical evaluation of its HCC Panel in China. In a blinded evaluation of 149 HCC patient and control samples, the HCC Panel achieved an AUROC of 0.97.
Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and fibrosis-cirrhosis. The Company’s mission is to reduce mortality and increase survival for the growing population at risk from serious liver diseases, including hepatocellular carcinoma or HCC, the most common form of liver cancer. Glycotest employs unique non-invasive blood tests based on proprietary serum biomarkers, biomarker panels and assay technology that exploit novel sugar-based disease signal chemistry.
The HCC Panel exhibited 93% sensitivity at 92% specificity in this product evaluation. In addition, in the AFP-negative cohort, the HCC Panel achieved an AUROC of 0.93 and identified 86% of the HCC patients undetected by AFP. In an early-stage HCC cohort, the HCC Panel achieved an AUROC of 0.96 and identified 78% of the HCC patients undetected by AFP. Glycotest’s proprietary HCC Panel blood test utilizes three novel fucosylated biomarkers along with three standard biomarkers and patient demographic data that are converted to a composite score by a proprietary algorithm. The HCC Panel score is intended to be used by a patient’s physician to determine the likelihood that the patient has HCC. The effective identification of patients with AFP-negative and/or potentially curable early-stage HCC are significant clinical needs unmet by currently available HCC tests.
In three separate clinical studies involving over 480 patients, the HCC Panel has now demonstrated the ability to identify AFP-negative and potentially curable early-stage HCC more effectively than AFP, the currently dominant blood test for HCC. Professor Anand Mehta, SmartState Endowed Chair of Proteomic Biomarkers at the Medical University of South Carolina and one of the innovators of the Glycotest HCC Panel, said, “It is gratifying to see that the clinical performance of the HCC Panel for the identification of patients with potentially curable early-stage HCC as well as those missed by AFP remains consistently high and superior to AFP in three separate clinical studies. The HCC Panel could have a profound impact on the lives of the growing number of patients who will develop HCC as a consequence of their underlying viral or non-viral hepatitis.”
###
About Glycotest, Inc.
Glycotest is a private liver disease diagnostics company commercializing novel clinical laboratory testing services for patients at risk for liver cancers and fibrosis-cirrhosis. The Company was founded in 2012 on proprietary technology that originated at the Philadelphia area institutions Baruch S. Blumberg Institute and Drexel University College of Medicine. Learn more at www.glycotest.com.
